Similar major cardiovascular outcomes between pure statin and ezetimibe-statin in comparable intensity for type 2 diabetes with extremely atherosclerotic risks
Abstract Atorvastatin 40 mg (ATOR 40) and ezetimibe 10 mg/simvastatin 20 mg (EZ-SIM 20) have similar reductions of low-density lipoprotein cholesterol (LDL-C) but cardiovascular (CV) outcomes between these two therapies are unclear. Our real-world cohort study is to test the hypothesis of pleiotropi...
Guardado en:
Autores principales: | Yu-Cheng Kao, Tien-Hsing Chen, Chi-Hung Liu, Jawl-Shan Hwang, Ching-Chung Hsiao, Yu-Sheng Lin, Chun-Tai Mao, Ming-Jui Hung, Yan-Rong Li |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d4191a5e624647d6b01ef66502373c4b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Baseline low-density lipoprotein cholesterol predicts the benefit of adding ezetimibe on statin in statin-naïve acute coronary syndrome
por: Jihaeng Im, et al.
Publicado: (2021) -
The association of atherosclerotic cardiovascular disease and statin use with inflammation and treatment outcomes in tuberculosis
por: Vignesh Chidambaram, et al.
Publicado: (2021) -
Effect of Statin Intensity on the Progression of Cardiac Allograft Vasculopathy
por: Tracey M Ellimuttil, et al.
Publicado: (2021) -
Prognostic effect of high-density lipoprotein cholesterol level in patients with atherosclerotic cardiovascular disease under statin treatment
por: Yi-Heng Li, et al.
Publicado: (2020) -
Statins and Insulin Resistance
por: GM Sanvee, et al.
Publicado: (2020)